Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Slides:

Advertisements

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The natural history of soy allergy

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Pavel Kolkhir, MD, Martin K

Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients Karin Hartmann, MD,

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point Emma C.Y. Hilton, PhD, Paul G.

Allergy testing in predicting outcome of open food challenge to peanut

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria Tse Wen Chang, PhD, Christina Chen, BS, Chien-Jen.

The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases Hiroshi Fujishima, MD, Naoko Okada, PhD, Kenji.

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

The quest for autoreactive antibodies in nasal polyps

Allison K. Martin, BS, Douglas G. Mack, PhD, Michael T

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase

Kerstin Bauermeister, MSc, Barbara K

Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria Thomas Gentinetta, MSc, Tatjana.

Priscilla Auyeung, PhD, Diana Mittag, PhD, Philip D

Component-resolved in vitro diagnosis of hazelnut allergy in Europe

Jeffrey M. Harris, MD, PhD, Christopher R

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcϵRI or anti-IgE autoantibodies

Real-life treatment of cholinergic urticaria with omalizumab

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy Princess U. Ogbogu, MD, Bruce S.

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia Hak-Ryul Kim, MD, Chang-Duk.

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P Christian Drouet, PhD, Anik Désormeaux,

Reply Journal of Allergy and Clinical Immunology

Systemic and localized seminal plasma hypersensitivity patients exhibit divergent immunologic characteristics Debajyoti Ghosh, PhD, Jonathan A. Bernstein,

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

Paradoxical psoriasis following anti–TNF therapy in ankylosing spondylitis: A population- based cohort study Jung Min Bae, MD, PhD, Hyuck Sun Kwon, MD,

Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: A case-control study Jonathan I. Silverberg,

Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis David W. Morris, MD, Emily M. Stucke, BA, Lisa.

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial Jonathan M. Spergel,

Carl Hamsten, MSc, PhD, Thi Anh T

Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma Cecilia K. Andersson, PhD, Anders Bergqvist, MSc, Michiko Mori,

Presentation transcript:

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan, MD, Karsten Weller, MD, Sabine Altrichter, MD, Per Stahl Skov, MD, Sidsel Falkencrone, PhD, Janko Brand, PhD, Arno Kromminga, PhD, Tomasz Hawro, MD, Martin K. Church, PhD, DSc, Marcus Maurer, MD Journal of Allergy and Clinical Immunology Volume 139, Issue 3, Pages 1059-1061.e1 (March 2017) DOI: 10.1016/j.jaci.2016.07.047 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Characteristics of the response to omalizumab treatment in patients with CSU. A, The percentage of responders (UAS7 ≤ 6) plotted against the day of response. The blue arrows indicate the days of omalizumab injections. B-F, ASST-positive and BHRA-positive omalizumab responders show slower onset of effects. B and E, Kaplan-Meier curves showing the proportion of patients with positive and negative BHRA (B) and positive and negative ASST (E) achieving response to therapy over time. C and F, Box-whiskers plots presenting median, interquartile range, maximum and minimum as well as individual dots of day to therapy response in patients with positive and negative BHRA (C) and ASST (F). D, Release of histamine in cell supernatants expressed as percentage of total histamine from donor cells in fast (≤8 days) and slow (<8 days) responders to omalizumab. The black solid vertical lines indicate median values, and the dotted horizontal line indicates cutoff for positive values of BHRA. As negative control, the buffy coat cells responded to a mixture of healthy sera with less than 5%. As a positive control we used anti-IgE, resulting in 45% release. Statistical analyses were performed using Kaplan-Meier estimator and log-rank statistics (B and E) or Mann-Whitney U test (C, D, and F). UAS7, 7-Day urticaria activity score. Journal of Allergy and Clinical Immunology 2017 139, 1059-1061.e1DOI: (10.1016/j.jaci.2016.07.047) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions